Search Within

Tiffany A Traina

Formats
  1. Meeting Abstract (137)
  2. Journal Article (95)
  3. Book Section (8)
  4. Review (6)
  5. Book Whole (2)
  6. Guidelines (1)
  7. Miscellaneous (1)
Groups
  1. Breast Medicine Service (250)
  2. Department of Medicine (250)
  3. Solid Tumor Oncology Division (250)
  4. Survivorship Research (250)
  5. Epidemiology and Biostatistics (99)
  6. Biostatistics Service (85)

More Groups

People
  1. Clifford Hudis (95)
  2. Sujata Patil (62)
  3. Ayca Gucalp (59)
  4. Larry Norton (56)
  5. Maura Dickler (34)
  6. Diana Lake (33)

More People

Years
  1. 2025 (3)
  2. 2024 (16)
  3. 2023 (8)
  4. 2022 (13)
  5. 2021 (17)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (76)
  2. Cancer Research (44)
  3. Breast Cancer Research and Treatment (16)
  4. Annals of Oncology (14)
  5. Clinical Cancer Research (11)
  6. Clinical Breast Cancer (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (77)
  2. American Association for Cancer Research (55)
  3. Springer (33)
  4. Elsevier Inc. (23)
  5. Oxford University Press (16)
  6. Future Medicine (5)

More Publishers

Results (250)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prevalence of hypomagnesemia in patients with HER2-positive breast cancer receiving pertuzumab treatment
    Meeting Abstract

    Proverbs-Singh, T. A.; Cadoo, K. A.; Torre, G.; Patil, S.; Gucalp, A.; Dang, C. T.; Hudis, C. A.; Glezerman, I. G.; Traina, T. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The role of LHRH agonists in ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast cancer: A systematic review and meta-analysis
    Meeting Abstract

    Munhoz, R. R.; Pereira, A. A. L.; Sasse, A. D.; Hoff, P. M.; Traina, T. A.; Hudis, C. A.; Marques, R. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
    Meeting Abstract

    Traina, T. A.; O'Shaughnessy, J.; Nanda, R.; Schwartzberg, L.; Abramson, V.; Cortes, J.; Peterson, A.; Tudor, I. C.; Blaney, M.; Steinberg, J. L.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)
    Meeting Abstract

    Isakoff, S. J.; Kim, S. B.; Im, S. A.; Dent, R. A.; Traina, T. A.; Valero, V.; Saura, C.; Yalamanchili, S.; Patel, P.; Oliveira, M.
    Cancer Research (2015)

    Fulltext@MSK | Save
  • A phase I/II study of neratinib plus temsirolimus in HER2+ metastatic breast cancer reveals ongoing HER2 pathway dependence in many patients despite several lines of HER2 targeted therapy
    Meeting Abstract

    Gajria, D.; Modi, S.; Saura, C.; Sakr, R.; Solano, K.; Won, H.; Pannu, H.; Patil, S.; Lake, D.; Traina, T.; more...
    Cancer Research (2015)

    Fulltext@MSK | Save
  • TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer
    Journal Article

    Isakoff, S. J.; Mayer, E. L.; He, L.; Traina, T. A.; Carey, L. A.; Krag, K. J.; Rugo, H. S.; Liu, M. C.; Stearns, V.; Come, S. E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Targeting the androgen receptor in prostate and breast cancer: Several new agents in development
    Journal Article

    Proverbs-Singh, T.; Feldman, J. L.; Morris, M. J.; Autio, K. A.; Traina, T. A.
    Endocrine-Related Cancer (2015)

    Fulltext@MSK | Save
  • Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
    Meeting Abstract

    Castan, J. C.; Schmid, P.; Awada, A.; Uppal, H.; Tudor, I. C.; Blaney, M. E.; Steinberg, J. L.; Yardley, D. A.; Hudis, C.; Traina, T. A.
    Annals of Oncology (2015)

    Fulltext@MSK | Save
  • Poly(ADP-ribose) polymerase (PARP) inhibitors for locally advanced or metastatic breast cancer
    Journal Article

    Khasraw, M.; Patil, S. M.; Traina, T. A.; Robson, M. E.
    Cochrane Database of Systematic Reviews (2014)

    Fulltext@MSK | Save